Skip to main content
Log in

Prolyl endopeptidases

  • Biomedicine & Diseases: Review
  • Published:
Cellular and Molecular Life Sciences Aims and scope Submit manuscript

Abstract.

This review describes the structure and function of prolyl endopeptidase (PEP) enzymes and how they are being evaluated as drug targets and therapeutic agents. The most well studied PEP family has a two-domain structure whose unique seven-blade β-propeller domain works with the catalytic domain to hydrolyze the peptide bond on the carboxyl side of internal proline residues of an oligopeptide substrate. Structural and functional studies on this protease family have elucidated the mechanism for peptide entry between the two domains. Other structurally unrelated PEPs have been identified, but have not been studied in detail. Human PEP has been evaluated as a pharmacological target for neurological diseases due to its high brain concentration and ability to cleave neuropeptides in vitro. Recently, microbial PEPs have been studied as potential therapeutics for celiac sprue, an inflammatory disease of the small intestine triggered by proline-rich gluten.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C. Khosla.

Additional information

Received 6 July 2006; received after revision 17 August 2006; accepted 1 November 2006

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gass, J., Khosla, C. Prolyl endopeptidases. Cell. Mol. Life Sci. 64, 345–355 (2007). https://doi.org/10.1007/s00018-006-6317-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00018-006-6317-y

Keywords.

Navigation